ASCO 2014 PD-1 survival rates

› Forums › General Melanoma Community › ASCO 2014 PD-1 survival rates

  • This topic is empty.
  • Post
    • June 9, 2014 at 2:36 am
    JerryfromFauq
    Participant

      Pembrolizumab (MK-3475) which targets the programmed death (PD-1) pathway produced a 1-year 69% survival rate.
      A combination of the investigative PD-1 inhibitor nivolumab in combination with another targeted agent ipilimumab (Yervoy) produced a 1-year survival rate of 85% and 2-year survival rate of 79% for advanced melanoma patients.

      ASCO: Targeting PD-1 Works in Advanced Melanoma:  Published: Jun 5, 2014
      http://www.medpagetoday.com/MeetingCoverage/ASCO/46159

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics